Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elevate-HF: Elecoglipron in HFpEF and HFmrEF
NCT07761117Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Primary completion
- Sep 2029
- Countries
- 32
01
Overview
A Phase 3 trial of elecoglipron in heart failure with preserved ejection fraction (HFpEF), heart failure with mildly reduced ejection fraction (HFmrEF), sponsored by AstraZeneca. Started Aug 2026; status: recruiting.
02
Drugs
elecoglipron
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mildly reduced ejection fraction (HFmrEF)
Beyond the preview
Go deeper on NCT07761117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07761117.